Cochrane Evidence Synthesis and Methods ►

Noradrenaline reuptake inhibitors (NRIs) for attention deficit hyperactivity disorder (ADHD) in adults

To assess the benefits and harms of noradrenaline reuptake inhibitors (NRIs) compared with placebo or no treatment, or any active pharmacological control for treating attention deficit hyperactivity disorder (ADHD) in adults.

This is a protocol.

Health topics:

Developmental, psychosocial & learning problems > Psychosocial problems > Attention deficit hyperactivity disorder (ADHD)

Insurance medicine > Sick Leave > Mental health

Published:

7 June 2018

Authors:

De Crescenzo F, Ziganshina L, Yudina EV, Kaplan Y, Ciabattini M, Wei Y, Hoyle CHV

See the full Review on

the Cochrane Library

►

Was this helpful? Donate.

If you found this evidence helpful, please consider donating to Cochrane. We are a charity that produces accessible evidence to help people make health and care decisions.
Donate
Print
PDF
Citation
De Crescenzo F, Ziganshina L, Yudina EV, Kaplan Y, Ciabattini M, Wei Y, Hoyle CHV. Noradrenaline reuptake inhibitors (NRIs) for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database of Systematic Reviews 2018, Issue 6. Art. No.: CD013044. DOI: 10.1002/14651858.CD013044